RxDoctor Payments Data

Michael Grodin, DO

Ophthalmology · Lutherville, MDNPI 1184670366

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $114, 2.1 times the $55 reported in 2020. That places this record below the midpoint for ophthalmology clinicians in MD, where the typical reported total is $1,143.

$278in general payments, 2019–2025

Across 12 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$59
  • Glaukos Corporation$36
  • AbbVie$28
  • Alcon$23
  • Astellas Pharma US Inc$22
  • Genentech USA, Inc.$22
  • plus $87 from 5 others
$24,838in research payments, 2019–2025

Across 3 payments — averaging $8279.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$25K

What the payments were for

  • Food & beverage$26094%
  • Gifts$176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$278 in reported general payments places this provider in the 25th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland →

Medicare billing

Part B allowed, 2024
$3,209,107
Medicare patients
1,932
Services billed
23,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SimbrinzaBrinzolamide/Brimonidine Tart32$6,418
LumiganBimatoprost11$5,185
Prednisolone Acetate84$4,023
Brimonidine Tartrate49$1,471
Latanoprost41$1,029
Ketorolac Tromethamine49$950
Atropine Sulfate24$742
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$593
Ofloxacin32$363
Dorzolamide Hcl16$238
Timolol Maleate17$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$23$6,41832 claims
AbbVieLumigan$28$5,18511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Lutherville

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →